By Colin Kellaher

Shares of Optinose plunge in premarket trading Wednesday after the pharmaceutical company said the U.S. Food and Drug Administration has extended the review of a request for expanded approval of its Xhance nasal spray by three months.

Optinose, which is seeking approval of Xhance as a treatment for chronic rhinosinusitis, said the FDA needs more time to review additional efficacy subset analyses the Yardley, Pa., company recently submitted at the agency's request.

Optinose said the FDA extended its target action date on the application to March 16, 2024.

Optinose shares, which closed Tuesday at $1.47, were recently down 22% to $1.14 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 06, 2023 08:33 ET (13:33 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
OptiNose (NASDAQ:OPTN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos OptiNose.
OptiNose (NASDAQ:OPTN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos OptiNose.